These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24708263)

  • 1. Three-dimensional tumor volume and serum alpha-fetoprotein are predictors of hepatocellular carcinoma recurrence after liver transplantation: refined selection criteria.
    Kashkoush S; El Moghazy W; Kawahara T; Gala-Lopez B; Toso C; Kneteman NM
    Clin Transplant; 2014 Jun; 28(6):728-36. PubMed ID: 24708263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
    Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
    Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
    Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
    Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma.
    Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Kim IH; Yi NJ; Lee KU
    Surgery; 2007 May; 141(5):598-609. PubMed ID: 17462459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation.
    Toso C; Meeberg G; Hernandez-Alejandro R; Dufour JF; Marotta P; Majno P; Kneteman NM
    Hepatology; 2015 Jul; 62(1):158-65. PubMed ID: 25777590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of total tumor volume and pretransplantation α-fetoprotein level as selection criteria for liver transplantation in patients with hepatocellular cancer.
    Grat M; Kornasiewicz O; Hołówko W; Lewandowski Z; Zieniewicz K; Paczek L; Krawczyk M
    Transplant Proc; 2013 Jun; 45(5):1899-903. PubMed ID: 23769067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the risk factors of untransplantable recurrence after primary curative resection for patients with hepatocellular carcinoma.
    Ho CM; Wu CY; Lee PH; Lai HS; Ho MC; Wu YM; Hu RH
    Ann Surg Oncol; 2013 Aug; 20(8):2526-33. PubMed ID: 23504121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation.
    Zhang Q; Shang L; Zang Y; Chen X; Zhang L; Wang Y; Wang L; Liu Y; Mao S; Shen Z
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):544-52. PubMed ID: 24614696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting recurrence and survival after living donor liver transplantation for hepatocellular carcinoma.
    Abdel-Wahab M; Sultan AM; Fathy OM; Salah T; Elshobary MM; Elghawalby NA; Yassen AM; Elsarraf WM; Elsaadany MF; Zalatah K
    Hepatogastroenterology; 2013; 60(128):1847-53. PubMed ID: 24719918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.
    Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
    JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation.
    Jiang T; Zhang XS; Pan F; Lyu SC; Wang J; Huang MX; He Q; Lang R
    Medicine (Baltimore); 2021 Jul; 100(26):e26487. PubMed ID: 34190174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum alpha-fetoprotein level per total tumor volume as a predictor of recurrence of hepatocellular carcinoma after resection.
    Sharma Y; Weaver MJ; Ludwig DR; Fowler K; Vachharajani N; Chapman WC; Crippin JS
    Surgery; 2018 May; 163(5):1002-1007. PubMed ID: 29284589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.
    Grąt M; Kornasiewicz O; Lewandowski Z; Hołówko W; Grąt K; Kobryń K; Patkowski W; Zieniewicz K; Krawczyk M
    World J Surg; 2014 Oct; 38(10):2698-707. PubMed ID: 24858191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of alpha-fetoprotein mRNA in peripheral blood in liver resection for hepatocellular carcinoma.
    Marubashi S; Nagano H; Wada H; Kobayashi S; Eguchi H; Takeda Y; Tanemura M; Umeshita K; Doki Y; Mori M
    Ann Surg Oncol; 2011 Aug; 18(8):2200-9. PubMed ID: 21301972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCC in living donor liver transplantation: can we expand the Milan criteria?
    Kwon CH; Kim DJ; Han YS; Park JB; Choi GS; Kim SJ; Joh JW; Lee SK
    Dig Dis; 2007; 25(4):313-9. PubMed ID: 17960066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma.
    Harrison LE; Koneru B; Baramipour P; Fisher A; Barone A; Wilson D; Dela Torre A; Cho KC; Contractor D; Korogodsky M
    J Am Coll Surg; 2003 Nov; 197(5):759-64. PubMed ID: 14585410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience.
    Varona MA; Soriano A; Aguirre-Jaime A; Garrido S; Oton E; Diaz D; Portero J; Bravo P; Barrera MA; Perera A
    Transplant Proc; 2015; 47(1):84-9. PubMed ID: 25645778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation.
    Lai Q; Avolio AW; Graziadei I; Otto G; Rossi M; Tisone G; Goffette P; Vogel W; Pitton MB; Lerut J;
    Liver Transpl; 2013 Oct; 19(10):1108-18. PubMed ID: 23873764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma.
    Berry K; Ioannou GN
    Liver Transpl; 2013 Jun; 19(6):634-45. PubMed ID: 23536495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.